Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
High-dimensional mass cytometry identifies T cell and B cell signatures predicting reduced risk of Plasmodium vivax malaria
Lisa J. Ioannidis, … , Rintis Noviyanti, Diana S. Hansen
Lisa J. Ioannidis, … , Rintis Noviyanti, Diana S. Hansen
Published June 15, 2021
Citation Information: JCI Insight. 2021;6(14):e148086. https://doi.org/10.1172/jci.insight.148086.
View: Text | PDF
Research Article Immunology Infectious disease

High-dimensional mass cytometry identifies T cell and B cell signatures predicting reduced risk of Plasmodium vivax malaria

  • Text
  • PDF
Abstract

IFN-γ–driven responses to malaria have been shown to modulate the development and function of T follicular helper (TFH) cells and memory B cells (MBCs), with conflicting evidence of their involvement in the induction of antibody responses required to achieve clinical immunity and their association with disease outcomes. Using high-dimensional single-cell mass cytometry, we identified distinct populations of TH1-polarized CD4+ T cells and MBCs expressing the TH1-defining transcription factor T-bet, associated with either increased or reduced risk of Plasmodium vivax (P. vivax) malaria, demonstrating that inflammatory responses to malaria are not universally detrimental for infection. Furthermore, we found that, whereas class-switched but not IgM+ MBCs were associated with a reduced risk of symptomatic malaria, populations of TH1 cells with a stem central memory phenotype, TH17 cells, and T regulatory cells were associated with protection from asymptomatic infection, suggesting that activation of cell-mediated immunity might also be required to control persistent P. vivax infection with low parasite burden.

Authors

Lisa J. Ioannidis, Halina M. Pietrzak, Ann Ly, Retno A.S. Utami, Emily M. Eriksson, Stephanie I. Studniberg, Waruni Abeysekera, Connie S.N. Li-Wai-Suen, Dylan Sheerin, Julie Healer, Agatha M. Puspitasari, Dwi Apriyanti, Farah N. Coutrier, Jeanne R. Poespoprodjo, Enny Kenangalem, Benediktus Andries, Pak Prayoga, Novita Sariyanti, Gordon K. Smyth, Leily Trianty, Alan F. Cowman, Ric N. Price, Rintis Noviyanti, Diana S. Hansen

×

Figure 1

Study cohort characteristics.

Options: View larger image (or click on image) Download as PowerPoint
Study cohort characteristics.
P. vivax symptomatic (n = 11) and asymptom...
P. vivax symptomatic (n = 11) and asymptomatic (n = 19) infected individuals as well as healthy immune controls (n = 24) were selected for analysis of immune responses to infection. Age (A) and sex (B) were not different while parasitemia was significantly higher in the symptomatic group (C). Other clinical parameters determined in the study include hematocrit (D), WBC count (E), platelet count (F), as well as the proportion of participants presenting with enlarged spleen (G) or liver (H). Antibody titers specific for P. vivax recombinant DBP were determined by ELISA (I). Boxes represent the 25th to 75th percentile, whiskers show the range (minimum to maximum), and lines represent the median. *P < 0.05, **P < 0.01, ***P < 0.001. Significance was determined by Kruskal-Wallis with Dunn’s multiple-comparison test (A, D, E, F, and I), Mann-Whitney test (C), or Fisher’s exact test (B, G, and H).

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts